Visualizing Progress With BTK Inhibitors: An Animated Journey Through the Mechanisms of Covalent and Non-Covalent Options

0.50 hr(s) | ABIM , CME , MOC

Specialty: BTK

Therapeutic Area(s): Hematology, Benign , Oncology

Release Date: November 19, 2021

Expiration Date: November 18, 2022

Location: Internet Activity Enduring

It’s well known that the BTK inhibitor agent class is highly effective across several B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. Less well understood are the factors that can limit the effectiveness of covalent BTK inhibitors and the emerging strategies that can overcome therapeutic resistance and intolerance, which provide a new option for managing relapsed disease. In this animated, visually enhanced activity, a hematology-oncology expert outlines the clinically relevant mechanistic aspects of covalent and noncovalent BTK inhibitors, mechanisms and patterns of resistance to covalent agents, and rationale for integrating novel approaches to combatting resistance and intolerance.

Access this activity
Share via
Copy link
Powered by Social Snap